Targeting signal transduction as a strategy to treat inflammatory diseases
暂无分享,去创建一个
[1] F. Martinon,et al. Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.
[2] V. Dixit,et al. Cryopyrin activates the inflammasome in response to toxins and ATP , 2006, Nature.
[3] S. Akira,et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3 , 2006, Nature.
[4] K. Papp,et al. A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. , 2006, Journal of the American Academy of Dermatology.
[5] H. Matsuyuki,et al. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. , 2006, Cellular & molecular immunology.
[6] L. O’Neill,et al. How Toll-like receptors signal: what we know and what we don't know. , 2006, Current opinion in immunology.
[7] M. Mann,et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6 , 2006, Nature.
[8] A. Shahangian,et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response , 2006, Nature.
[9] Ki-Young Lee,et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. , 2005, Genes & development.
[10] Jun Wang,et al. Small-Molecule Inhibition of TNF-α , 2005, Science.
[11] S. Akira,et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement , 2005, The Journal of experimental medicine.
[12] S. Targan,et al. Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.
[13] Jean-Philippe Spano,et al. Proteasome inhibition: a new approach for the treatment of malignancies. , 2005, Bulletin du cancer.
[14] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[15] P. Moynagh,et al. The NF-κB pathway , 2005, Journal of Cell Science.
[16] Michael Karin,et al. IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy , 2005 .
[17] A. Hoffmann,et al. Molecular Determinants of Crosstalk between Nuclear Receptors and Toll-like Receptors , 2005, Cell.
[18] P. Parren,et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. , 2005, Arthritis and rheumatism.
[19] T. Herdegen,et al. Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. , 2005, Trends in pharmacological sciences.
[20] C. Hawkey,et al. Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis , 2005, Inflammatory bowel diseases.
[21] F. Martinon,et al. NLRs join TLRs as innate sensors of pathogens. , 2005, Trends in immunology.
[22] C. Nickerson-Nutter,et al. mTOR--beyond transplantation. , 2005, Current opinion in pharmacology.
[23] C. Battram,et al. Preclinical Profile of Ciclesonide, a Novel Corticosteroid for the Treatment of Asthma , 2005, Journal of Pharmacology and Experimental Therapeutics.
[24] C. Dominguez,et al. p38 MAP kinase inhibitors: many are made, but few are chosen. , 2005, Current opinion in drug discovery & development.
[25] U. Siebenlist,et al. Control of lymphocyte development by nuclear factor-κB , 2005, Nature Reviews Immunology.
[26] K. Honda,et al. Spatiotemporal regulation of MyD88–IRF-7 signalling for robust type-I interferon induction , 2005, Nature.
[27] Dairong Wang,et al. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. , 2005, Current opinion in pharmacology.
[28] Jong-Suk Kim,et al. PPAR‐gamma modulates allergic inflammation through up‐regulation of PTEN , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[29] C. Coban,et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-α induction , 2005, The Journal of experimental medicine.
[30] D. Trune,et al. Identification of a Peptide Derived from Vaccinia Virus A52R Protein That Inhibits Cytokine Secretion in Response to TLR-Dependent Signaling and Reduces In Vivo Bacterial-Induced Inflammation1 , 2005, The Journal of Immunology.
[31] J. Dancey. Inhibitors of the mammalian target of rapamycin , 2005, Expert opinion on investigational drugs.
[32] S. Ghosh,et al. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. , 2005, Arthritis and rheumatism.
[33] Michael Karin,et al. Nod2 Mutation in Crohn's Disease Potentiates NF-κB Activity and IL-1ß Processing , 2005, Science.
[34] Andrea Messori,et al. New drugs for rheumatoid arthritis [6] (multiple letters) , 2004 .
[35] B. Aronow,et al. Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers , 2004 .
[36] J. Dean,et al. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. , 2004, Cellular signalling.
[37] A. Lindén,et al. Interleukin-17 family members and inflammation. , 2004, Immunity.
[38] M. Humbert. Ciclesonide: a novel inhaled corticosteroid , 2004, Expert opinion on investigational drugs.
[39] Domenico Spina,et al. The potential of PDE4 inhibitors in respiratory disease. , 2004, Current drug targets. Inflammation and allergy.
[40] Tomohiro Watanabe,et al. NOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responses , 2004, Nature Immunology.
[41] J. O’Shea,et al. A new modality for immunosuppression: targeting the JAK/STAT pathway , 2004, Nature Reviews Drug Discovery.
[42] R. Fleischmann,et al. Does safety make a difference in selecting the right TNF antagonist? , 2004, Arthritis research & therapy.
[43] P. Emery,et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.
[44] J. Kay,et al. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. , 2004, Rheumatology.
[45] F. Martinon,et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. , 2004, Immunity.
[46] C. Dinarello. Unraveling the NALP-3/IL-1beta inflammasome: a big lesson from a small mutation. , 2004, Immunity.
[47] Giulio Superti-Furga,et al. A physical and functional map of the human TNF-α/NF-κB signal transduction pathway , 2004, Nature Cell Biology.
[48] C. Jefferies,et al. Interferon Regulatory Factor-3-mediated Activation of the Interferon-sensitive Response Element by Toll-like receptor (TLR) 4 but Not TLR3 Requires the p65 Subunit of NF-κ* , 2003, Journal of Biological Chemistry.
[49] Martin M Holtmann. RDP-58 (SangStat Medical). , 2003, IDrugs : the investigational drugs journal.
[50] M. Dougados,et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. , 2003, The New England journal of medicine.
[51] J. O’Shea,et al. Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor , 2003, Science.
[52] R. Herbst,et al. Gefitinib: current and future status in cancer therapy. , 2003, Clinical advances in hematology & oncology : H&O.
[53] L. O’Neill. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. , 2003, Current opinion in pharmacology.
[54] J. Rigas,et al. P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy , 2003 .
[55] A. Manning,et al. Targeting JNK for therapeutic benefit: from junk to gold? , 2003, Nature Reviews Drug Discovery.
[56] T. Bártfai,et al. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[57] A. Bowie,et al. The Toll-IL-1 receptor adaptor family grows to five members. , 2003, Trends in immunology.
[58] Guo-Ping Zhou,et al. Triggering the Interferon Antiviral Response Through an IKK-Related Pathway , 2003, Science.
[59] E. Lubberts. The role of IL-17 and family members in the pathogenesis of arthritis. , 2003, Current opinion in investigational drugs.
[60] S. Kushwaha,et al. Transplant immunosuppressant agents and their role in autoimmune rheumatic diseases , 2003, Current opinion in rheumatology.
[61] T. Maniatis,et al. IKKε and TBK1 are essential components of the IRF3 signaling pathway , 2003, Nature Immunology.
[62] H. Amemiya,et al. Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment , 2003, Journal of Pharmacology and Experimental Therapeutics.
[63] R. Gay,et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. , 2003, The American journal of pathology.
[64] T. Moseley,et al. Interleukin-17 family and IL-17 receptors. , 2003, Cytokine & growth factor reviews.
[65] I. Haga,et al. The Poxvirus Protein A52R Targets Toll-like Receptor Signaling Complexes to Suppress Host Defense , 2003, The Journal of experimental medicine.
[66] M. Zeitz,et al. Pralnacasan (vertex pharmaceuticals). , 2003, IDrugs : the investigational drugs journal.
[67] Sophie Janssens,et al. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. , 2003, Molecular cell.
[68] Michael Kracht,et al. Transcriptional and post-transcriptional control of gene expression in inflammation. , 2002, Cytokine.
[69] J. Saklatvala,et al. Dexamethasone Causes Sustained Expression of Mitogen-Activated Protein Kinase (MAPK) Phosphatase 1 and Phosphatase-Mediated Inhibition of MAPK p38 , 2002, Molecular and Cellular Biology.
[70] D. Taub,et al. Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway. , 2002, Blood.
[71] M. Shlomchik,et al. Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.
[72] O. Kassel,et al. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP‐1 , 2001, The EMBO journal.
[73] Mourad Sahbatou,et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.
[74] Judy H. Cho,et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.
[75] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[76] D. Underwood,et al. Inhibition of p38 MAP Kinase , 2001 .
[77] A. Manning,et al. Jun N-terminal kinase in rheumatoid arthritis. , 1999, The Journal of pharmacology and experimental therapeutics.
[78] J. Corbin,et al. Cyclic GMP Phosphodiesterase-5: Target of Sildenafil* , 1999, The Journal of Biological Chemistry.
[79] W. Koenig,et al. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.
[80] L. O’Neill,et al. Signal transduction pathways activated by the IL‐1 receptor family: ancient signaling machinery in mammals, insects, and plants , 1998, Journal of leukocyte biology.
[81] Jerry L. Adams,et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.
[82] J. Hsuan,et al. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of hsp27 , 1994, Cell.
[83] L Bibbs,et al. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. , 1994, Science.
[84] M. Feldmann,et al. TNF alpha--a pivotal role in rheumatoid arthritis? , 1992, British journal of rheumatology.
[85] N. Gay,et al. Drosophila Toll and IL-1 receptor , 1991, Nature.
[86] G. Nabel,et al. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[87] David Baltimore,et al. Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism , 1986, Cell.
[88] Tomohiro Watanabe,et al. Signalling pathways and molecular interactions of NOD1 and NOD2 , 2006, Nature Reviews Immunology.
[89] K. Fan Chung. Phosphodiesterase inhibitors in airways disease. , 2006, European journal of pharmacology.
[90] Tobias Gabriel,et al. Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. , 2005, Current topics in medicinal chemistry.
[91] K. Lehle,et al. Predominant inhibition of interleukin-6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is affected and mitotic arrest takes place. , 2005, Transplantation proceedings.
[92] Michael Karin,et al. The IKK NF-κB system: a treasure trove for drug development , 2004, Nature Reviews Drug Discovery.